These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 19570818

  • 1. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?
    Bonzano L, Roccatagliata L, Mancardi GL, Sormani MP.
    Mult Scler; 2009 Sep; 15(9):1043-7. PubMed ID: 19570818
    [Abstract] [Full Text] [Related]

  • 2. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 3. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F, Kümpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismüller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP.
    BMC Neurol; 2006 May 23; 6():19. PubMed ID: 16719908
    [Abstract] [Full Text] [Related]

  • 4. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G, Filippi M, Wolinsky JS.
    Ann Neurol; 2001 Mar 23; 49(3):290-7. PubMed ID: 11261502
    [Abstract] [Full Text] [Related]

  • 5. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
    Zhao Y, Traboulsee A, Petkau AJ, Li D.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1092-7. PubMed ID: 18003938
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
    Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicanò G, Konze A, Siracusa G, Taiuti R, Amaducci L.
    Arch Neurol; 2005 Dec 25; 62(12):1843-7. PubMed ID: 16344342
    [Abstract] [Full Text] [Related]

  • 7. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.
    McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, Patronas N, Maloni H, McFarlin DE.
    Ann Neurol; 1992 Dec 25; 32(6):758-66. PubMed ID: 1471866
    [Abstract] [Full Text] [Related]

  • 8. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
    Krapf H, Morrissey SP, Zenker O, Zwingers T, Gonsette R, Hartung HP, MIMS Study Group.
    Neurology; 2005 Sep 13; 65(5):690-5. PubMed ID: 16157900
    [Abstract] [Full Text] [Related]

  • 9. The effect on MRI of gammaglobulin treatment in relapsing multiple sclerosis.
    Sørensen PS.
    Mult Scler; 2000 Oct 13; 6 Suppl 2():S14-7. PubMed ID: 11188772
    [Abstract] [Full Text] [Related]

  • 10. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.
    Smith ME, Stone LA, Albert PS, Frank JA, Martin R, Armstrong M, Maloni H, McFarlin DE, McFarland HF.
    Ann Neurol; 1993 May 13; 33(5):480-9. PubMed ID: 8498825
    [Abstract] [Full Text] [Related]

  • 11. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
    Paolillo A, Piattella MC, Pantano P, Di Legge S, Caramia F, Russo P, Lenzi GL, Pozzilli C.
    J Neurol; 2004 Apr 13; 251(4):432-9. PubMed ID: 15083288
    [Abstract] [Full Text] [Related]

  • 12. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
    De Stefano N, Filippi M, Hawkins C, 9011 study group.
    J Neurol Sci; 2008 Mar 15; 266(1-2):44-50. PubMed ID: 17897678
    [Abstract] [Full Text] [Related]

  • 13. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
    Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T, Laquinimod in Relapsing MS Study Group.
    Neurology; 2005 Mar 22; 64(6):987-91. PubMed ID: 15781813
    [Abstract] [Full Text] [Related]

  • 14. Segmentation of gadolinium-enhanced lesions on MRI in multiple sclerosis.
    Datta S, Sajja BR, He R, Gupta RK, Wolinsky JS, Narayana PA.
    J Magn Reson Imaging; 2007 May 22; 25(5):932-7. PubMed ID: 17457804
    [Abstract] [Full Text] [Related]

  • 15. Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy.
    Schocke MF, Berger T, Felber SR, Wolf C, Deisenhammer F, Kremser C, Seppi K, Aichner FT.
    Neuroimage; 2003 Oct 22; 20(2):1253-63. PubMed ID: 14568494
    [Abstract] [Full Text] [Related]

  • 16. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history.
    Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF.
    Ann Neurol; 1991 May 22; 29(5):548-55. PubMed ID: 1859184
    [Abstract] [Full Text] [Related]

  • 17. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis.
    Cocco E, Marchi P, Sardu C, Russo P, Paolillo A, Mascia M, Solla M, Frau J, Lorefice L, Massole S, Floris G, Marrosu M.
    Mult Scler; 2007 Sep 22; 13(8):975-80. PubMed ID: 17468439
    [Abstract] [Full Text] [Related]

  • 18. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.
    Metz LM, Zhang Y, Yeung M, Patry DG, Bell RB, Stoian CA, Yong VW, Patten SB, Duquette P, Antel JP, Mitchell JR.
    Ann Neurol; 2004 May 22; 55(5):756. PubMed ID: 15122721
    [No Abstract] [Full Text] [Related]

  • 19. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
    Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H, ACT Investigators.
    Mult Scler; 2008 Apr 22; 14(3):370-82. PubMed ID: 18208877
    [Abstract] [Full Text] [Related]

  • 20. Magnetic resonance imaging of inflammatory lesions in the spine in ankylosing spondylitis clinical trials: is paramagnetic contrast medium necessary?
    Hermann KG, Landewé RB, Braun J, van der Heijde DM.
    J Rheumatol; 2005 Oct 22; 32(10):2056-60. PubMed ID: 16206370
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.